Which company manufactures the popular GLP-1 medicine Mounjaro?

Eli Lilly manufactures the GLP-1 medicine Mounjaro.

Eli Lilly and Company developed and markets Mounjaro, whose active ingredient is tirzepatide. In the United States, Mounjaro is approved to improve blood-sugar control in adults with type 2 diabetes alongside diet and exercise. Tirzepatide acts on both GIP and GLP-1 receptors, distinguishing it from medicines that target only the GLP-1 receptor.

Eli Lilly was founded in Indianapolis in 1876 by Colonel Eli Lilly, a pharmaceutical chemist and Union Army veteran. The company grew through insulin, antibiotics, psychiatric medicines, cancer treatments, and other therapies. Its later diabetes portfolio helped make it a major global pharmaceutical company.

Mounjaro is often confused with Zepbound, which also contains tirzepatide but has a different United States indication: chronic weight management for eligible adults and adolescents. Product approvals and brand names vary by country, so medical decisions should rely on local regulators and clinicians.